A Two-Part, Randomized Study of Dermacyte® Amniotic Wound Care Matrix

NANot yet recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Diabetic Foot Ulcer
Interventions
DEVICE

Dermacyte Matrix

The appropriate square centimeters of Dermacyte Matrix is applied directly to the target DFU that is free of debris and necrotic tissue. The Dermacyte Matrix will be applied at weekly intervals or for up to 10 applications.

OTHER

Standard of Care (SOC)

SOC therapy will consist of debridement of nonviable tissue, saline-moistened non-occlusive dressing, weight off-loading to decrease pressure on extremity, aggressive treatment of infection and arterial revascularization if indicated at weekly intervals or for up to 10 applications.

Sponsors
All Listed Sponsors
lead

Merakris Therapeutics

INDUSTRY

NCT06444906 - A Two-Part, Randomized Study of Dermacyte® Amniotic Wound Care Matrix | Biotech Hunter | Biotech Hunter